1795.TW
1795.TW
TW0001795003
LOTUS PHARMACEUTICAL CO
Loading chart...

Company Profile

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.

Related stocks

6472.TW
6472.TW • Taiwan
BORA PHARMACEUTICALS CO LTD
421 TWD
1.68B USD 1Y -36%
4516.T
4516.T • Japan
NIPPON SHINYAKU CO
3,372 JPY
1.44B USD 1Y -0.4%
688321.SS
688321.SS • China
SHENZHEN CHIPSCREEN BIOSCIENCES
24.31 CNY
1.61B USD 1Y -23.6%
4540.T
4540.T • Japan
TSUMURA & CO
3,772 JPY
1.78B USD 1Y +5%
COHANCE.NS
COHANCE.NS • India
COHANCE LIFESCIENCES LTD
441 INR
1.74B USD 1Y -48.6%
300725.SZ
300725.SZ • China
PHARMABLOCK
51.01 CNY
1.78B USD 1Y +22.3%
4887.T
4887.T • Japan
SAWAI GROUP HOLDINGS CO LTD
1,629.5 JPY
1.19B USD 1Y -18.6%
JUBLPHARMA.BO
JUBLPHARMA.BO • India
JUBILANT PHARMOVA LIMITED
931.2 INR
1.52B USD 1Y -14.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
46.3% p.a.
Max Drawdown (5Y)
-52.3%
Sharpe Ratio (5Y)
0.22
Beta Factor
0.66
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 240%.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (46.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -67.1% in the extended horizon.
ende